Pantocrinum is a tonic and stimulating adaptogen based on the maral (red deer) antlers extract.
The healing properties of maral antlers were well-known in ancient Chinese mythology and in ancient Roman medicine. They were widely used in Chinese and Korean medicine. In Russia, the healing properties of maral antlers were revealed in the 18th century, though the research on the matter started in 1930s. The red deer antlers extract was registered under the brand name Pantocrinum in 1970. The drug can be used as part of complex therapy of asthenia (overwork), neurasthenia and hypotension. The drug is available in pharmacies without a prescription.
Since the 19th century, marals are bred in captivity in order to obtain their antlers. In Russia, the breeding is most developed in Altai Republic. Sawing off the antlers is painless and harmless for the deer as they have a natural ability to lose and regrow their antlers annually.
Maral antlers extract contains biologically active substances (peptides, amino acids, phospholipids and microelements) that have a pronounced tonic and adaptogenic effect that improves physical and mental performance, especially in case of asthenia and monotonous activity. The drug has a positive effect on the sexual function, including the dysfunctions caused by aging and exposure to noxious factors.
The drug has adaptogenic properties, stimulating the central nervous and cardiovascular systems, activating skeletal muscle tone and motor activity of the gastrointestinal tract. It contains phospholipids and microelements that increase endurance, stabilise the blood pressure in hypotension cases and stimulate the gastrointestinal tract.
- can be used as a tonic aimed at increasing endurance and mental performance;
- treatment of asthenia , neurasthenia and neuroses;
- treatment of asthenic syndrome after acute infectious diseases;
- as part of complex therapy of hypotension.
Atherosclerosis, chronic heart failure, stenocardia, hypercoagulation, inflammation of the kidneys, diarrhoea, hypotension, malignant neoplasms, excitability, sleep disorders, pregnancy and breast-feeding and children under 12 years of age.